Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL

Approximately 80% of patients with diffuse large B-cell lymphoma achieve a complete response following chemoimmunotherapy as defined by PET scan. However, not all patients who fail to achieve a metabolic complete response are destined to relapse. In a number of these patients, the PET scan is falsely positive (i.e., 20%-40% in several large series), particularly when the PET scan score is Deauville 4. Reflexively intervening with salvage systemic therapy or radiotherapy in these patients is potentially harmful. It appears that very sensitive measurements of circulating tumor DNA might be able to differentiate between patients who are unlikely to relapse and those with residual lymphoma. It is important to remember that lymphoma is not the only condition that can make a PET scan abnormal and to consider alternate diagnosis that should be managed differently.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-02-26
DOI
https://doi.org/10.1182/bloodadvances.2025019273
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL

JO Armitage, Julie M. Vose, Dan L Longo, Matthew A Lunning
Blood Advances
Lymphoma Diagnosis and Treatment
article

Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL

JO Armitage, Julie M. Vose, Dan L Longo, Matthew A Lunning
article en

Abstract

Approximately 80% of patients with diffuse large B-cell lymphoma achieve a complete response following chemoimmunotherapy as defined by PET scan. However, not all patients who fail to achieve a metabolic complete response are destined to relapse. In a number of these patients, the PET scan is falsely positive (i.e., 20%-40% in several large series), particularly when the PET scan score is Deauville 4. Reflexively intervening with salvage systemic therapy or radiotherapy in these patients is potentially harmful. It appears that very sensitive measurements of circulating tumor DNA might be able to differentiate between patients who are unlikely to relapse and those with residual lymphoma. It is important to remember that lymphoma is not the only condition that can make a PET scan abnormal and to consider alternate diagnosis that should be managed differently.

Blood Advances
New England Law (US), Journal of Medical Insight (US), University of Nebraska Medical Center (US)
Openalex Percentile: Top 43%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.